
Bicycle Therapeutics fell 54.1% from $6.32 to $2.90, behind the S&P 500's +4.7%. Its worst day was Feb 3 (−7.6%), and its low came Nov 20 at $2.90.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Bicycle Therapeutics closed at its highest level of the year, 19.0% above where the year started.
+6.1% · S&P 500 +0.7%
EPS of $-0.29 beat the $-0.97 estimate on $48.0M revenue (est. $8.3M).
Story events cover the past 12 months · Times ET
+0.4% · S&P 500 +0.3%
EPS of $-0.87 missed the $-0.62 estimate on $887,000.00 revenue (est. $7.6M).
−0.2% · S&P 500 +1.0%
EPS of $-0.72 missed the $-0.53 estimate on $629,000.00 revenue (est. $5.4M).
+3.9% · S&P 500 +1.7%
Bicycle Therapeutics shares rose 18.6%, while the S&P 500 rose 0.7%.
+18.6%, the year's best day · S&P 500 +0.7%
EPS of $-0.15 beat the $-0.43 estimate on $34.1M revenue (est. $14.0M).
−1.5% · S&P 500 −0.4%
Where it ended: a close of $2.90 on Nov 20, 2026. Up next: Q4 2026 earnings on Mar 16, 2027 (EPS est. $-0.54, revenue est. $4.6M).
Nothing in the past 12 months.
All BCYC dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCYC and SPY from Benzinga historical bars. Not investment advice.